SAMHD1 and non-small cell lung carcinoma: It also hinders the activation of the STING pathway, which can inhibit the expression of IFN1 and weaken anti-tumor immunity in NSCLC treatment [22, 23].However, Wang et al. have revealed that the overexpression of SAMHD1 inhibits the proliferation of lung cancer cells [24].